$LLY

LLYEli Lilly and Company Common Stock

What are people saying about Eli Lilly and Company (LLY) stock on YouTube?

In the past 7 days (As of 11-18), 1 YouTube channel discussed Eli Lilly and Company (LLY) in 3 entries. Most recent: Schwab Network, 2026-11-16.

All takes and content in this window

As of 11-18
11-16
Schwab NetworkPublished 2026-11-16
“Adam Coons On Defense; "No Touch" on NVDA, Avoiding HD and LOW Pre-Earnings”
$LLYBullish
AI summary · Eli Lilly is somewhat defensive; continued obesity-drug launches, with Retatrutide/GLP-3 next, may make it a game-changer that eliminates the competition. The speaker says LLY, like Google, has 10 to 20% upside potential, and both can outperform for different reasons and in different scenarios.

Share like Google that you liked. I mean, it saw that decline after the earnings, but it was in a somewhat upward trend. And Eli Lily. Do you think both of these stocks have a 10 to 20% upside potential?

As for Eli Lilly, it is once again a somewhat defensive stock , but the products they are putting forward and we see a continuation of the introduction of various obesity drugs.

I believe "Retatrotide" is next in the production line. Some people call it "GLP-3". This drug is likely to be a game-changer for them in this field, and may eliminate the rest of the competition.

11-13
Schwab NetworkPublished 2026-11-13
“PPI Mostly Cool, AI at "Crossroads" Amid NVDA CEO Search”
$LLYBullish
11-12
Schwab NetworkPublished 2026-11-12
“The Big 3: JNJ, LLY, AAPL”
$LLYBullish
AI summary · Eli Lilly is technically strong and the speaker expects a measured upward move: faster moving averages favor bulls, though it has not convincingly broken the 14.50 ceiling and RSI shows a bearish divergence. He prefers an options structure to capture upside while limiting downside, targeting 1560–1600 and an ideal 8–10% rise; the stock is expensive and hard for options, while healthcare should stay relatively strong into 2027.

Your next choice is also in the healthcare sector. We have Eli Lilly. I mean, perhaps Eli Lilly's chart is more technically clear. So , what is your outlook for Lilly? A similar view.

The momentum is definitely there from a technical standpoint. But again, I fundamentally believe that the healthcare sector will continue to demonstrate relative strength as we enter 2027.

It is an expensive stock. It is difficult to structure options positions on it due to the size of the stock and the cost of the options as well. However, I still believe there are opportunities, and that's why when I looked at the trading example today, the focus was on structuring a deal around options.

Therefore, to some extent, we identify downside risks with the ability to capture upward price movements.

Showing 3 / 3 on this page
See this ticker’s full history